Cornerstone Therapeutics (CRTX) Acquires Cardiokine
Cornerstone Therapeutics yesterday announced the acquisition of Cardiokine, Inc. The merger, effective December 30, 2011, will have Cornerstone receiving all outstanding shares of Cardiokine, which recently completed Phase III clinical trials for its compound, lixivaptan. Based in North Carolina, Cornerstone Therapeutics is a specialty pharmaceutical company focused on products for the respiratory, hospital and related markets. The company focuses on acquiring, developing and marketing said products, and leveraging existing business in niche portions of those same markets. The acquisition will grant Cornerstone worldwide rights to investigational therapy using lixivaptan, a compound designed to treat hyponatremia. Hyponatremia is a condition that…